申请人:Taisho Pharmaceutical Co., Ltd.
公开号:US05478945A1
公开(公告)日:1995-12-26
A thiazoline derivative represented by the formula: ##STR1## [wherein R.sup.1 is cyano, carbamoyl, thiocarbamoyl, morpholinothiocarbonyl, alkylthioimidoyl, amidino, substituted amidino or imidazolin-2-yl, R.sup.2 is alkyl or aralkyl, R.sup.3 is hydrogen or alkyl, R.sup.4 is hydroxyl, alkoxy, substituted alkoxy or amino, l is an integer of 1 to 5] and salts thereof have fibrinogen receptor antagonism and cell adhesion factor antagonism, and are useful as therapeutic agents for ischemic diseases and atherosclerosis diseases, and metastasis inhibitory agents of tumors.
一种由以下公式表示的噻唑啉衍生物:##STR1## [其中R.sup.1为氰基,氨甲酰基,硫氨甲酰基,吗啉硫氨基甲酰基,烷基硫代亚胺基,胺基甲酰基,取代的胺基甲酰基或咪唑啉-2-基,R.sup.2为烷基或芳基烷基,R.sup.3为氢或烷基,R.sup.4为羟基,烷氧基,取代的烷氧基或氨基,l为1至5的整数]及其盐具有纤维蛋白原受体拮抗作用和细胞粘附因子拮抗作用,可用作缺血性疾病和动脉粥样硬化疾病的治疗剂,以及肿瘤的转移抑制剂。